EHI
Eagle Health Investments Portfolio holdings
AUM
$405M
This Quarter Return
+16.18%
1 Year Return
+14.19%
3 Year Return
+134.25%
5 Year Return
–
10 Year Return
–
AUM
$560M
AUM Growth
+$560M
(+6.6%)
Cap. Flow
+$13.8M
Cap. Flow
% of AUM
2.47%
Top 10 Holdings %
Top 10 Hldgs %
68.23%
Holding
31
New
4
Increased
5
Reduced
7
Closed
5
Top Buys
| 1 |
UnitedHealth
UNH
|
$44.3M |
| 2 |
Insmed
INSM
|
$34.4M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$19.1M |
| 4 |
Exact Sciences
EXAS
|
$17.9M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
$9.24M |
Top Sells
| 1 |
Danaher
DHR
|
$28.4M |
| 2 |
Transmedics
TMDX
|
$22M |
| 3 |
Natera
NTRA
|
$17.2M |
| 4 |
Sarepta Therapeutics
SRPT
|
$13.4M |
| 5 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
$12.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
United Therapeutics
UTHR
$13.8B
| $53.4M | 9.36% | 167,499 -12,000 | -7% | -$3.82M |
|
|
2
Natera
NTRA
$23.1B
| $51.3M | 9% | 474,114 -158,600 | -25% | -$17.2M |
|
3
Icon
ICLR
$13.8B
| $46.9M | 8.22% | 149,590 | – | – |
|
|
4
UnitedHealth
UNH
$281B
| $44.3M | 7.76% | +86,900 | New | +$44.3M |
|
5
argenx
ARGX
$43.6B
| $38.2M | 6.7% | 88,890 +4,300 | +5% | +$1.85M |
|
|
6
Insmed
INSM
$28.8B
| $34.4M | 6.04% | +513,700 | New | +$34.4M |
|
7
Illumina
ILMN
$15.8B
| $33.3M | 5.83% | 318,754 | – | – |
|
8
DexCom
DXCM
$29.5B
| $31.3M | 5.48% | 275,718 -9,200 | -3% | -$1.04M |
|
9
IQVIA
IQV
$32.4B
| $25.8M | 4.52% | 121,895 | – | – |
|
|
10
Exact Sciences
EXAS
$8.98B
| $23M | 4.03% | 544,200 +423,200 | +350% | +$17.9M |
|
|
11
Ultragenyx Pharmaceutical
RARE
$2.89B
| $21.6M | 3.78% | 524,500 +224,800 | +75% | +$9.24M |
|
|
12
Transmedics
TMDX
$3.92B
| $20M | 3.51% | 132,861 -145,794 | -52% | -$22M |
|
|
13
BioMarin Pharmaceuticals
BMRN
$11.2B
| $19.1M | 3.35% | +231,800 | New | +$19.1M |
|
14
Alnylam Pharmaceuticals
ALNY
$58.5B
| $18.5M | 3.25% | 76,256 +27,900 | +58% | +$6.78M |
|
15
Inspire Medical Systems
INSP
$2.77B
| $18.3M | 3.21% | 136,603 +14,400 | +12% | +$1.93M |
|
16
Guardant Health
GH
$8.41B
| $18.1M | 3.18% | 626,909 -103,300 | -14% | -$2.98M |
|
17
Procept Biorobotics
PRCT
$2.23B
| $15.7M | 2.75% | 257,089 -80,129 | -24% | -$4.9M |
|
18
Agios Pharmaceuticals
AGIO
$2.19B
| $14.3M | 2.5% | 330,830 | – | – |
|
19
Intuitive Surgical
ISRG
$170B
| $12.6M | 2.21% | 28,290 -7,300 | -21% | -$3.25M |
|
20
4D Molecular Therapeutics
FDMT
$288M
| $9.72M | 1.7% | 462,911 | – | – |
|
21
Lantheus
LNTH
$3.73B
| $3.47M | 0.61% | 43,200 | – | – |
|
22
Viking Therapeutics
VKTX
$3.04B
| $2.39M | 0.42% | 45,000 | – | – |
|
23
Werewolf Therapeutics
HOWL
$59.9M
| $1.71M | 0.3% | 700,000 | – | – |
|
24
Immunocore
IMCR
$1.62B
| $1.57M | 0.28% | 46,300 | – | – |
|
|
GRAL
25
GRAIL, Inc. Common Stock
GRAL
$1.18B
| $817K | 0.14% | +53,124 | New | +$817K |
|